- TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS
-
Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.
- -
-
-
- 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS
-
Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
- -
-
-
- 1-R 1 -3, 3-difluoro-4-R 2-piperidine and its derivatives preparation method
-
The invention relates to a preparation method for 1-R1-3,3-difluoro-4-R2-piperidine shown as a formula (I) and derivatives thereof. In the formula (I), R1 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R4 is C1-C9 alkyl, aryl or benzyl; R5 is C1-C9 alkyl, aryl or benzyl; R2 is CH2NHR6 or CH2CO2H; R6 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R3 is hydrogen, C1-C9 alkyl, aryl or benzyl; and the above optional groups are not substituted or substituted by a substituted group consisting of one or more of alkyl, haloalkyl, hydroxyalkyl, halogen, alkyloxy or hydroxyl. The preparation method is characterized by comprising steps shown by a reaction formula in the specification.
- -
-
-